ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Seres Therapeutics Inc

Seres Therapeutics Inc (MCRB)

1.13
-0.09
(-7.45%)
Closed July 23 4:00PM
1.14
0.01
( 0.88% )
Pre Market: 7:09AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.14
Bid
1.10
Ask
1.14
Volume
3,139
0.00 Day's Range 0.00
0.54 52 Week Range 5.29
Market Cap
Previous Close
1.13
Open
-
Last Trade
3
@
1.14
Last Trade Time
07:11:05
Financial Volume
-
VWAP
-
Average Volume (3m)
4,668,996
Shares Outstanding
151,447,763
Dividend Yield
-
PE Ratio
-1.50
Earnings Per Share (EPS)
-0.75
Revenue
126.33M
Net Profit
-113.72M

About Seres Therapeutics Inc

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the func... Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Seres Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MCRB. The last closing price for Seres Therapeutics was $1.13. Over the last year, Seres Therapeutics shares have traded in a share price range of $ 0.54 to $ 5.29.

Seres Therapeutics currently has 151,447,763 shares outstanding. The market capitalization of Seres Therapeutics is $171.14 million. Seres Therapeutics has a price to earnings ratio (PE ratio) of -1.50.

MCRB Latest News

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5...

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 PR Newswire BRIDGEWATER, N.J., June 6, 2024 Transaction ensures Nestlé Health Science will...

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.22-16.17647058821.361.531.0348563151.33124324CS
40.37348.6310299870.7671.530.695746780921.06131209CS
120.1211.76470588241.021.530.563446689960.94495962CS
26-0.07-5.785123966941.211.530.5444102680.92122972CS
52-3.46-75.21739130434.65.290.5441086901.32007776CS
156-6.31-84.69798657727.4511.690.5423886593.37581718CS
260-1.83-61.61616161622.9738.50.5417950806.65962105CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 2.42
(134.95%)
6.17M
DRMADermata Therapeutics Inc
$ 2.59
(99.23%)
11.09M
HOTHHoth Therapeutics Inc
$ 1.50
(54.33%)
10.72M
PIRSPieris Pharmaceuticals Inc
$ 11.87
(48.75%)
86.51k
BBLGBone Biologics Corporation
$ 1.85
(48.00%)
3.49M
VWEVintage Wine Estates Inc
$ 0.073
(-34.76%)
935.54k
CONNConns Inc
$ 0.3502
(-30.93%)
135.81k
SAGESage Therapeutics Inc
$ 9.50
(-27.37%)
6.93k
TCBPTC BioPharm Holdings PLC
$ 0.60
(-25.00%)
502
ATPCAgape ATP Corporation
$ 0.162
(-24.65%)
496.56k
ALLRAllarity Therapeutics Inc
$ 0.2135
(28.23%)
29.51M
DRMADermata Therapeutics Inc
$ 2.59
(99.23%)
11.09M
HOTHHoth Therapeutics Inc
$ 1.50
(54.33%)
10.72M
SLNASelina Hospitality PLC
$ 0.0291
(11.92%)
9.93M
NUZENuZee Inc
$ 2.42
(134.95%)
6.17M

MCRB Discussion

View Posts
Monksdream Monksdream 4 days ago
MCRB under $2
👍️0
TechandBio TechandBio 6 days ago
Feel Great about the $2.00 calls I bought yesterday.
Close over 1.50 next!

$MCRB
👍️0
TechandBio TechandBio 6 days ago
was buying Seres for .77 a month ago. I'm holding for $2.00+ same for $ICCM expect a similar move soon.

$MCRB
👍️0
Cosa Cosa 6 days ago
The past few days have been great! Sold off 15% of my position today. Taking some off the table for profits.
👍️0
glenn1919 glenn1919 7 days ago
MCRB.....................https://stockcharts.com/h-sc/ui?s=MCRB&p=W&b=5&g=0&id=p86431144783
👍️0
TechandBio TechandBio 1 week ago
Just sold my MCRB for a double. Looking for a 10x in ICCM Cure early breast cancer 97% after multiple 5 year independent data studies and late stage breast cancer data with large tumors 93%
$MCRB
👍️0
RiddleGuru99 RiddleGuru99 4 weeks ago
Jeanfm. Any update on this or is it basically dead?
👍️0
ConnorMic ConnorMic 1 month ago
are u still there Jean fm
👍️0
ConnorMic ConnorMic 1 month ago
He has loads of rsu’s at 3 bucks and 5 bucks. He would come out swimming if they sold the whole company. To me he is flagships guy though so he’ll do whatever they tell him and seems like flagship wants to keep things moving as a clinical stage company. See-155 is phase 1. No way nestle partners and gives them upfront cash at this point. They might sell the rest of the portfolio to someone else or partner with someone. As it stands today this would go from a pharma with revenue and a commercialized product to a very early stage bio and it’s hard to imagine long term institutional investors are over the moon about this. So if it stays as is can’t believe they have the vote and stock price is giving them that signal. Lots of time for them to change the deal.
👍️0
Cosa Cosa 1 month ago
Selling the company is out for one simply reason. Management doesn't hold too much shares. For instance CEO Eric Shaff's salary in 2023 was estimated to be about $685k with other compensation totaling over $3m. According to my etrade account Eric holds 140,698 shares on 5/15/2024. If Nestle offered $5.20 a share, that make his shares worth $731,629. I'm not sure how many more options or RSU's would vest which would increase this number. But $700k is an easy "No" for him as he would be out of a job and makes more keeping it. This is all my opinion and for entertainment purposes.

https://finance.yahoo.com/news/increases-seres-therapeutics-inc-nasdaq-164726562.html
👍️0
Cosa Cosa 1 month ago
If they do sell VOWST and strike a deal for SER-155, that would be more bullish.

This is from SER-109 article in 2021 but changed it to SER-155 for entertainment purposes.
Under the terms of the agreement, Nestlé Health Science will utilize its global pharmaceutical business Aimmune Therapeutics and will assume the role of lead commercialization party. Seres will receive license payments of $175 million up front, and an additional $125 million upon FDA approval of SER-155. The agreement also includes sales target milestones which, if achieved, could total up to $225 million. Seres will be responsible for development and pre-commercialization costs in the U.S. Upon commercialization, Seres will be entitled to an amount equal to 50% of the commercial profits.

Original Article:
https://www.businesswire.com/news/home/20210701005405/en/Seres-Therapeutics-Nestl%C3%A9-Health-Science-Announce-SER-109-Co-Commercialization-License-Agreement
👍️0
Cosa Cosa 1 month ago
Not sure if shareholders would vote in favor of $230M. Maybe up to $300M

If you read this from the article below. And based on their last ER. They have about $102M in liabilities. They have cash of about $125M, which is expected to be runway to Q4 2024.

With capital expected from transaction they will pay off $102M and have a cash runway to Q4 2025. They are going to sell the remaining 50% rights for about $230M. This would pay off debt and leave them with $250M cash runway. Assuming that $125M was our runway to Q4 this year and another $125M is for the year 2025. Probably have a milestone payment in there also.

Clip from article below.
Seres expects to use the capital from this transaction to fully retire its senior secured debt facility with Oaktree Capital Management, and support the further advancement of SER-155 and its other cultivated microbiome product candidates. Based on Seres' current cash, its future operating plans, and the capital expected to be obtained from the transaction, the Company anticipates being able to extend its cash runway into Q4 2025, subject to performance under the transition services agreement.
Source:
https://ih.advfn.com/stock-market/NASDAQ/seres-therapeutics-MCRB/stock-news/93996839/seres-therapeutics-enters-into-memorandum-of-under

All just made up numbers for entertainment purposes.
👍️0
ConnorMic ConnorMic 1 month ago
Comment v’as Tu Jean. As Tu encore des connection chez nestle? As tu des nouvelles?
👍️0
ConnorMic ConnorMic 2 months ago
At the time maybe that was total shares outstanding ? Maybe minus the ones nestle already owns.
👍️ 1
ConnorMic ConnorMic 2 months ago
Agreed merci Jean
👍️0
Cosa Cosa 2 months ago
Tomorrow $0.75 needs to hold
👍️0
Carmen for the win Carmen for the win 2 months ago
Dear Jean, thank you for the info you have shared. In one of your previous posts you wrote "119000000 À 5.20" what did you mean by that?
👍️0
Cosa Cosa 2 months ago
I'm no longer doubting that you knew something. Just didn't work in the way it was originally planned. Thanks Jean
👍️0
ConnorMic ConnorMic 2 months ago
Ok merci Jean. Pense-Tu que seres a du non valeur apres ca ?
👍️0
JeanFM JeanFM 2 months ago
J'AI VU LE PROJET CHEZ VEVE L'OFFRE ÉTAIT 5,20 $ POUR CHAQUE ACTION DE SERES CLASSE A

Nestlé S.A voulait que l'entreprise et les actionnaires soient payés. Blâmez la direction et non Nestlé S.A ici à Veve
👍️0
JeanFM JeanFM 2 months ago
L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024
👍️0
JeanFM JeanFM 2 months ago
L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024
👍️0
JeanFM JeanFM 2 months ago
L'ACCORD ORIGINAL ÉTAIT DE 5 $ ET 20 CENTS POUR CHAQUE SPECTACLE SERES PAR NESTLE S.A, CONVENU DANS LE PROJET DE MARS 2024
👍️0
Cosa Cosa 2 months ago
If that is the case, Seres shareholders would be absolutely angered. EGM and fire everyone. But we won't know unless Nestle goes public with the offer. Which I doubt they will, because if they ink this deal in would be a win win for them. They would have full rights to VOWST and not have to take on Seres debt.
👍️ 1
JeanFM JeanFM 2 months ago
l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune
👍️ 1
JeanFM JeanFM 2 months ago
l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune
👍️0
JeanFM JeanFM 2 months ago
l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune
👍️0
JeanFM JeanFM 2 months ago
l'accord initial était de 5,20 $ pour chaque action, payé à Seres par Nestlé S.A.

La sortie d'aujourd'hui n'était PAS l'offre originale. Nestlé S.A voulait acheter toutes les actions pour 5,20 $ chacune
👍️0
andrewflying andrewflying 2 months ago
Thank you for your input! Could you please elaborate on what you said regarding the news for next week. Apparently, the market hates today's announcement.
👍️0
Cosa Cosa 2 months ago
This is bad news. Seres will be going backwards to a clinical stage company. The only long term benefit will be whatever Royalty deal they can secure for VOWST. With the deal they currently have in place Nestle already has 50% of the rights. They have already paid $175M upfront and another $125M after the approval. So currently Nestle is in for $300M. On the PR today the terms say any new deal will basically terminate the previous deal. So the remaining $225M milestone payments are out. How much is the remaining 50% rights worth? Maybe they will try $500M with new milestone payments + a small percentage or sales?

But in the end if you look at where Seres is today, they have about $125M cash runway (This is with the $300M they got the past 2 years). So even if they get a $500M, it will only take about 2 years for that money to be gone. The cost of RD is really expensive. SER-155 is still in phase 1!

Seres entered into an agreement with Nestlé Health Science in July 2021 to jointly commercialize SER-109 in the U.S. and Canada. Under the terms of the agreement, Nestlé Health Science will use its global pharmaceutical business, Aimmune Therapeutics, and will assume the role of lead commercialization party. Seres has received an upfront license payment of $175 million and will receive an additional $125 million upon FDA approval of SER-109. The agreement also includes sales target milestones which, if achieved, would total up to $225 million. Seres will be responsible for development and pre-commercialization costs in the U.S. Upon commercialization, Seres will be entitled to an amount equal to 50% of the commercial profits.

Source: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-announces-confirmatory-results
👍️ 1
ConnorMic ConnorMic 2 months ago
Tu nous a dit le prix de seres est 5.20
👍️0
FrostyStar1 FrostyStar1 2 months ago
You said Nestle was getting the company for 5.20 that didn't happen

Nestle gets vowst and shareholders get nothing
👍️0
Carmen for the win Carmen for the win 2 months ago
Dear Jean, could you please explain what you mean by the 119000000 number?
thank you
👍️0
QueenVolcano96 QueenVolcano96 2 months ago
Why MCRB share price is not $5.20 yet? Seems no acquisition at $5.20 a share?
👍️0
JeanFM JeanFM 2 months ago
Oui VOWST, Nestle S.A ou VOWST

Le prix convenu sur cette offre est de 5 dollars et 20 cents

J'ai vu l'accord de Nestlé S.A.

J'ai raison. J'ai dit du 5 au 9 juin pour un accord.

119000000 À 5.20
👍️0
JeanFM JeanFM 2 months ago
Oui VOWST, Nestle S.A ou VOWST

Le prix convenu sur cette offre est de 5 dollars et 20 cents

J'ai vu l'accord de Nestlé S.A.

J'ai raison. J'ai dit du 5 au 9 juin pour un accord.

119000000 À 5.20
👍️0
FrostyStar1 FrostyStar1 2 months ago
Not true, you said Nestle gets the company. Nestle does not get the company.
👍️0
JeanFM JeanFM 2 months ago
Comme j'ai dit

Tout a été correct

Le prix de VOWST est de 5,20 en dollars
👍️0
JeanFM JeanFM 2 months ago
J'étais en vacances en Allemagne

Recherchez les nouvelles SER155 la semaine prochaine. Nestlé S.A. en est très satisfaite, mais la valeur vaut désormais le double.

La date initiale de juin pourrait être négociée

Jean
👍️0
trendzone trendzone 2 months ago
There is a bunch of scm bag hedge funds or others with 18m shares short, that could use a good big squeezing,and are responsible for it being below a buck, they are some of the most corrupt SOB's out there, that need to get blown out,and wiped out.
👍️0
Carmen for the win Carmen for the win 2 months ago
Dear JeanFM, I hope all is well. Any news from Switzerland ?
👍️0
Genya90 Genya90 2 months ago
Investing in stocks is a risky thing, MCRB’s products is one in a kind! Nobody has it , it’s a Fact and tells all story.
Upside is huge if you got at right time
👍️0
ConnorMic ConnorMic 2 months ago
Agreed on all points !
👍️0
Genya90 Genya90 2 months ago
$6-7
👍️0
Cosa Cosa 2 months ago
I'm investing in the potential of an FDA approved drug that shows great efficacy. And the company's share price took an absolute beating since it's approval.

Not a fan of management as they should have had an offering in place prior to approval to take advantage of the higher price at the time. The cash runway is slim as R&D comes at a great expense. Also sales depends on another company or better worded as Seres revenue depends on another company which is quite scary.

In my opinion SER-155 has a high risk of failure. These people are extremely vulnerable and fighting for their lives. This drug would only help in one aspect of the patients overall condition. So it would be a really targeted market. The penetration into this market will be a difficult road if it makes it that far.

So overall investing here is very risky and buyout would be a blessing.

This is all my opinion. Good luck!
👍️0
KobeF KobeF 2 months ago
$5 buyout?
👍️0
ConnorMic ConnorMic 2 months ago
Regardless of Jean fm most folks were invested in a buyout premise. And there was huge dark pool buying two weeks again. I still think we are on track for either a buyout or great ser-155 readout but yeah believing Jean fm timelines is a bit far fetched.
👍️0
Cosa Cosa 2 months ago
I'm pretty sure it was a pump. It started right after it hit all time lows. Once whatever date passes and nothing happens, all those accounts will never be seen again.
👍️0
RiddleGuru99 RiddleGuru99 2 months ago
Still think this will happen?
👍️0
EclipseKingdom46 EclipseKingdom46 2 months ago
je suis MF Naej, et ce n'est pas un conseil financier.

je n'ai aucune idée de quand quelque chose va arriver. Bonne chance à nous tous.
👍️0

Your Recent History

Delayed Upgrade Clock